Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 368

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 19
Chunk 368
---
 Effect of settlement, curtailment                                       ( 58,787                -        
  Amortization of pension related net loss                                       -                -        
  Net (gain)/loss, end of period                                         ( 105,759                161,104  
  Prior service cost, beginning of period                                        -                -        
  Amortization of prior service cost                                       ( 3,094                ( 3,031  
  Prior service cost end of period                                         ( 3,094                ( 3,031  
  Total unrecognized pension (credit) cost, end of period      $         ( 108,853      $         158,073  

F-20

NLS PHARMACEUTICS LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The weighted average of the key assumptions used
to compute the benefit obligations were as follows:

                                                        2024      2023  
 ────────────────────────────────────────────────────────────────────────
  Discount rate                                         0.95      1.45  
  Rate of increase in compensation level                0.65      0.65  
  Interest credit rate on savings accounts              1.25      1.45  
  Expected long-term rate of return on plan assets      2.15      2.30  
  Inflation rate                                        1.25      1.25  

The assumption of the expected long-term rate
of return on plan assets was based on the long-term historical rates of returns for the different investment categories which were adjusted,
where appropriate, to reflect financial market developments. The investment risk is borne by the insurer and the reinsurer respectively,
and the investment decision is taken by the board of trustees of the collective insurance. The accumulated benefit obligation as of December
31, 2024, and 2023 amounted to $2,213,177and $809,028, respectively.

Note 9

Commitments and Contingencies:

Commitments

On March 10, 2021, the Company entered into a
license agreement with Novartis Pharma AG (“ Novartis”), whereby the Company obtained, on an exclusive basis in the U. S., all
of the available data referred to and included in the original new drug application (“ NDA”) for Sanorex® (mazindol) submitted
to the U. S. Food and Drug Administration (“ FDA”) in February 1972. The agreement encompasses